02142 和鉑醫藥－Ｂ
按盘价 
1.200 -0.020 (-1.639%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | 9.899% | -53.344% | -41.060% | -129.364% | -88.184% |
| 股东资金回报率 (%) | 21.424% | -86.844% | -47.153% | -285.306% | N/A |
| 资本运用回报率 (%) | 13.871% | -87.359% | -57.096% | -81.610% | -130.774% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 97.727% | 99.680% | 96.820% | 96.817% | 88.503% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 28.559% | -319.398% | -3089.903% | -2066.740% | -1171.452% |
| 税前边际利润率 (%) | 25.342% | -336.998% | -3199.373% | -2102.772% | -1247.241% |
| 纯利率 (%) | 25.471% | -337.495% | -3198.166% | -2101.063% | -1244.879% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 3.277 X | 2.785 X | 5.867 X | 14.453 X | 2.595 X |
| 速动比率 (X) | 3.277 X | 2.771 X | 5.867 X | 14.453 X | 2.595 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 47.641% | 60.150% | 21.054% | 7.133% | 320.790% |
| 总债项 / 总资产比率 (%) | 28.892% | 39.173% | 6.896% | 0.444% | 2.745% |
| 净债项 / 总资产比率 (%) | -32.525% | -34.799% | -69.709% | -91.339% | -45.300% |
| 总债项 / 股东资金比率 (%) | 55.016% | 97.956% | 8.725% | 0.478% | N/A |
| 长期债项 / 股东资金比率 (%) | 23.817% | 52.273% | 7.205% | 0.077% | N/A |
| 净债项 / 股东资金比率 (%) | -61.933% | -87.019% | -88.189% | -98.306% | N/A |
| 净现金 / (债项) ($) | 7.43千万 | 8.08千万 | 1.97亿 | 3.55亿 | 3.15千万 |
| 每股净现金 / (债项) ($) | 0.097 | 0.105 | 0.256 | 0.462 | -- |
| 总债项 / 资本运用比率 (%) | 40.166% | 57.887% | 8.070% | 0.475% | 3.699% |
| 利息盈利率 (X) | 6.858 X | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | N/A | 2931.231日 | N/A | N/A | N/A |
| 应收贸易帐周转率日数 (日) | 121.204日 | 32.066日 | 45.837日 | 35.305日 | 64.021日 |
| 应付贸易帐周转率日数 (日) | 76.245日 | 215.549日 | 1438.352日 | 223.510日 | 482.603日 |
| 备注： | 实时报价更新时间为25/11/2024 17:55 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | USD 1,424,000 |
| 增长率 | -51.266% |
| 每股盈利/(亏损) | USD 0.002 |
| 每股账面资产净值 ($) | USD 0.160 |